Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
59,112,975
-
Total 13F shares
-
36,693,312
-
Share change
-
+4,483,983
-
Total reported value
-
$394,818,289
-
Put/Call ratio
-
1139%
-
Price per share
-
$10.76
-
Number of holders
-
102
-
Value change
-
+$48,696,476
-
Number of buys
-
52
-
Number of sells
-
56
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q2 2023
As of 30 Jun 2023,
Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,693,312 shares.
The largest 10 holders included
BIOIMPACT CAPITAL LLC, CHI Advisors LLC, BVF INC/IL, FRANKLIN RESOURCES INC, BlackRock Inc., VANGUARD GROUP INC, BRAIDWELL LP, AMERICAN INTERNATIONAL GROUP, INC., Nextech Invest Ltd., and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
102
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.